SPL 801 B
Alternative Names: SPL-801-BLatest Information Update: 23 Oct 2023
Price :
$50 *
At a glance
- Originator Small Pharma
- Developer Cybin
- Class Antidepressants; Cyclohexanes; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 23 Oct 2023 Small Pharma has been acquired and merged into Cybin
- 28 Aug 2023 No recent reports of development identified for preclinical development in Depressive disorders in United Kingdom (PO)
- 15 Jul 2022 Small Pharma has patent protection for certain salt forms of 2R,6R-hydroxynorketamine (6-HNK) in USA